Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company's cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.

This content is available to members only.

If you are an existing member, please LOGIN

Note a member? Sign up for a FREE account ($89 per month value), and get immediate access. Free offer expires March 15, 2019.

Register New Account

Free Membership

Log in if you wish to renew an existing subscription.

Username

Email

First Name

Last Name

Password

Password Again

.

Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2
subscribe@wallstreetreporter.com.

Nightfood Ice Cream (OTC: NGTF) Scores Two Major National Media Hits: CEO Interviewed on Yahoo Finance PM, and a Feature on Today.com

March 21, 2019 Comments Off on Nightfood Ice Cream (OTC: NGTF) Scores Two Major National Media Hits: CEO Interviewed on Yahoo Finance PM, and a Feature on Today.com
CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

March 21, 2019 Comments Off on CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV
Medicine Man Technologies, Inc., (OTC: MDCL) to Present at Sidoti & Company,Spring 2019 Conference

March 21, 2019 Comments Off on Medicine Man Technologies, Inc., (OTC: MDCL) to Present at Sidoti & Company,Spring 2019 Conference
CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

March 12, 2019 Comments Off on CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)
Nightfood Ice Cream (OTC: NGTF) Expanding Distribution to Sixteen States; Second Production Run This Week, Initial Feedback is Strong

March 11, 2019 Comments Off on Nightfood Ice Cream (OTC: NGTF) Expanding Distribution to Sixteen States; Second Production Run This Week, Initial Feedback is Strong
FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

Register New Account

Related Articles